We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Patient Selection Approach May Change for Minimally Invasive Stroke Treatment

By HospiMedica International staff writers
Posted on 09 Aug 2012
New findings show that patients presenting with ischemic stroke may be effectively treated with endovascular or minimally invasive therapy well beyond the eight-hour treatment window currently established to be standard by most neurointerventional practitioners. More...


The multicenter study evaluated the use of computed tomography (CT) perfusion imaging, regardless of time from symptom onset, in selecting patients for endovascular treatment, a technique which utilizes devices or clot-busting drugs directly at the problem site in the brain to dispel clots and restore blood flow.

CT perfusion imaging is used in combination with other imaging techniques to determine which areas of the brain are irreversibly injured from a stroke, and which areas are still alive, but at great risk. The study’s findings were presented July 24, 2012, at the Society of Neurointerventional Surgery (SNIS) 9th annual meeting, held in San Diego (CA, USA).

Study data collected from the Medical University of South Carolina (MUSC; Charleston, SC, USA), Swedish Medical Center (Denver, Co, USA), and the University of Florida (Gainesville, USA) demonstrated that out of 247 patients for whom perfusion imaging was used, 42.5% showed a 90-day modified Rankin Scale score (a measure of the degree of disability in people who have suffered a stroke) of 0%-2% (considered a good functional outcome), which is comparable to results from all other significant trials to date that assessed endovascular therapy conducted under eight hours.

Notably, this latest study showed no significant difference in treatment outcomes between patients treated in less than eight hours (42.8%) and those treated over eight hours (41.9%). Furthermore, immediately following treatment, restoration of blood flow was accomplished in 76% of patients, with a higher success rate in those treated over eight hours (81.1%) as opposed to those treated under eight hours (71.7%). All study subjects underwent mechanical thrombectomy, or treatment utilizing devices to reopen the affected vessel.

“This is truly a landmark study in that it definitively shows that perfusion imaging as a patient selection criteria for endovascular therapy is a successful evaluation tool, whether patients are presenting at three hours out from their stroke or 11 hours,” said Aquilla Turk, DO, professor of radiology and neurosurgery, director of neurointerventional surgery of MUSC. “Broadly speaking, these results could transform our approach to patient selection and ultimately may mean that we will be able to treat significantly more patients and reduce the devastating burden of this disease on individuals and families.”

Study data were collected from 2007 to 2011 from patients with a mean age of 65.9 presenting with an average score of 18 on the US National Institutes of Health Stroke Scale (NIHSS), a standardized measure used to clinically evaluate the degree of impairment of a stroke in such areas as consciousness vision, speech, movement, language, and sensation. Anyone with an NIHSS score of less than eight was excluded from the study. The overall mean time from symptom onset to treatment start was eight hours, with an average time to treat of 4.8 hours in the group of patients treated in less than eight hours, and 16.4 hours in the group treated over eight hours. The 90-day mortality rate for study subjects was 23%. The safety and efficacy data showed that utilizing an imaging based approach to patient selection is comparable to benchmark data established in all of the time-based clinical stroke trials to date.

Currently, neurointerventionalists chiefly utilize devices to restore blood flow in stroke patients as they can more immediately disperse the clot while medications frequently take time to dissolve the occlusion and pose the added risks of bleeding. Treatment with devices is accomplished by maneuvering the instrument through a catheter inserted into the groin area and threaded through the arteries to the site of the clot. The first device utilized to undertake endovascular stroke treatment was US Food and Drug Administration (FDA)-approved in 2004, and since that time many other technologies have made their way into the neurointerventionist’s treatment armory.

Related Links:
Medical University of South Carolina
Swedish Medical Center
University of Florida


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.